Fig. 3

Pseudoprogression in a 65-year-old patient with lung carcinoma treated with nivolumab (anti-PD-1). Baseline axial CT showed a lung mass in the upper right lobe with normal adrenal glands. At a 38-week follow-up (FU), there was a good reduction in the size of the lung mass, but a new lesion appeared in the right adrenal gland (arrow). The patient was maintained under the same treatment. At 44-week follow-up, the right adrenal mass disappeared, confirming the diagnosis of pseudoprogression